KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomarin Pharmaceutical (BMRN) EPS (Weighted Average and Diluted) (2018 - 2025)

Biomarin Pharmaceutical (BMRN) has disclosed EPS (Weighted Average and Diluted) for 14 consecutive years, with -$0.24 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Weighted Average and Diluted) fell 136.92% year-over-year to -$0.24, compared with a TTM value of $1.8 through Dec 2025, down 18.55%, and an annual FY2025 reading of $1.8, down 18.55% over the prior year.
  • EPS (Weighted Average and Diluted) was -$0.24 for Q4 2025 at Biomarin Pharmaceutical, down from -$0.15 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $1.24 in Q2 2025 and bottomed at -$0.31 in Q4 2021.
  • Average EPS (Weighted Average and Diluted) over 5 years is $0.26, with a median of $0.18 recorded in 2022.
  • The sharpest move saw EPS (Weighted Average and Diluted) plummeted 381.82% in 2021, then skyrocketed 7688.88% in 2023.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$0.31 in 2021, then soared by 99.57% to -$0.0 in 2022, then surged by 7688.88% to $0.1 in 2023, then skyrocketed by 550.0% to $0.65 in 2024, then crashed by 136.92% to -$0.24 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for BMRN at -$0.24 in Q4 2025, -$0.15 in Q3 2025, and $1.24 in Q2 2025.